HCRT and pancreatic neoplasm: When treating chemoresistant pancreatic tumors, which had developed resistance to Nab-paclitaxel or gemcitabine through succeeding mice xenografts, it was discovered that orexin A exhibited a remarkable capability to significantly impede tumor growth (Voisin et al., 2022).